Canine-Assisted ANxiety Reduction IN Emergency Care IV (CANINE IV)

July 18, 2023 updated by: Nicholas Pettit, Indiana University

Canine-Assisted ANxiety Reduction IN Emergency Care IV (CANINE IV)

Prior literature demonstrates that human stress can be reduced with exposure to animals. This study challenges current dogma by introducing a widely available, low cost method of dog therapy to reduce patient and provider stress. The objectives of this study are to determine if interaction with a certified therapy dog and handler can;

  • decrease reported anxiety levels in emergency department (ED) patients,
  • decrease salivary cortisol in ED patients,
  • decrease total morphine equivalent dosing in the emergency department or at discharge and/or,
  • decrease reported stress levels in emergency department providers caring for participating patients

when compared to usual care.

Study Overview

Status

Withdrawn

Intervention / Treatment

Study Type

Interventional

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact Backup

  • Name: Courtney Linville
  • Phone Number: 317-880-3877
  • Email: ctlinvil@iu.edu

Study Locations

    • Indiana
      • Indianapolis, Indiana, United States, 46202
        • Eskenazi Health System

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

Patients

  • Age 18-89 years
  • Chronic pain, defined as pain on most days for >6 weeks
  • Triage pain score >6 out of 10

OR

  • Age 18-89 years
  • Currently experience crisis, including suicidality, or
  • Meet the standard of a provider assessment of "severe stress" defined by their identification that the patient meets a score of greater than six on the FACES stress scale

Providers

• Faculty, residents, advanced practitioners, and nurses who work in the ED and identify themselves as being the nurse or physician of record for the enrolled patients.

Therapy Dog Handlers

• Handler of a certified therapy dog and volunteer of Eskenazi's Therapy Dog Program

Exclusion Criteria:

Patients

  • Violent behavior
  • Overt intoxication
  • Non-English speaking
  • Any reported prior fear or adverse reaction to dogs

Providers

• Any reported prior fear or adverse reaction to dogs

Therapy Dog Handlers

• None

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Placebo Comparator: Control
Emergency department patients enrolled in the control arm will receive usual care. Emergency department providers enrolled in the control arm will work their shift as usual.
Control
Active Comparator: Intervention
Emergency department patients and providers in the intervention arm will be exposed to and/or interact with a certified therapy dog and handler
Exposure to certified therapy dogs and their handler.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Morphine equivalent narcotic administration in emergency department patients with chronic pain
Time Frame: Date of enrollment until emergency department discharge, up to 72 hours
Total morphine equivalent narcotic administration while in the emergency department or as a discharge prescription will be recorded for enrolled patients.
Date of enrollment until emergency department discharge, up to 72 hours
Change in reported stress levels in ED patients with chronic pain using Wong-Baker FACES Scale (10 = worst)
Time Frame: Baseline and T1 (~45 minutes after baseline)
Change in self reported stress levels of emergency department patients using a Wong-Baker FACES Scale for anxiety between baseline and T1
Baseline and T1 (~45 minutes after baseline)
Change in salivary cortisol in ED patients with chronic pain
Time Frame: Baseline and T1 (~45 minutes after baseline)
Change in salivary cortisol levels in emergency department patients between baseline and T1
Baseline and T1 (~45 minutes after baseline)
Number of narcotic, sedative and/or neuroleptic doses administered in ED patients with emotional crisis
Time Frame: Date of enrollment until emergency department discharge, up to 72 hours
Number of narcotic, sedative and/or neuroleptic doses administered in ED patients with emotional crisis
Date of enrollment until emergency department discharge, up to 72 hours
Change in reported stress levels in ED patients with emotional crisis using Wong-Baker FACES Scale (10 = worst)
Time Frame: Baseline and T1 (~45 minutes after baseline)
Change in self reported stress levels of emergency department patients using a Wong-Baker FACES Scale for anxiety between baseline and T1
Baseline and T1 (~45 minutes after baseline)
Change in salivary cortisol in ED patients with emotional crisis
Time Frame: Baseline and T1 (~45 minutes after baseline)
Change in salivary cortisol levels in emergency department patients between baseline and T1
Baseline and T1 (~45 minutes after baseline)

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Change in salivary cortisol levels in emergency department patients
Time Frame: Baseline and T1 (~45 minutes after baseline)
Change in salivary cortisol levels in emergency department patients between baseline and T1
Baseline and T1 (~45 minutes after baseline)

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Estimated)

March 1, 2022

Primary Completion (Estimated)

December 31, 2022

Study Completion (Estimated)

December 31, 2022

Study Registration Dates

First Submitted

February 12, 2020

First Submitted That Met QC Criteria

February 26, 2020

First Posted (Actual)

February 27, 2020

Study Record Updates

Last Update Posted (Actual)

July 20, 2023

Last Update Submitted That Met QC Criteria

July 18, 2023

Last Verified

July 1, 2023

More Information

Terms related to this study

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Chronic Pain

Clinical Trials on Control

3
Subscribe